Proteasome inhibitors have been suggested as potential anticancer agents in many clinical trials. Recent evidence indicates that proteasomal deubiquitinase (DUB) inhibitors, bearing a different mechanism from that of traditional proteasome inhibitors, would be appropriate candidates for new anticancer drug development. In the present study, we describe the deubiquitinase inhibition of 19S regulatory particles (19S RP) by AC17, a 4-arylidene curcumin analog synthesized in our laboratory. Although 4-arylidene curcumin analogs were reported to act as inhibitory kB (IkB) kinase (IKK) inhibitors, AC17 instead induced a rapid and marked accumulation of ubiquitinated proteins without inhibiting proteasome proteolytic activities. In contrast to its parent compound, curcumin, which is a proteasome proteolytic inhibitor, AC17 serves as an irreversible deubiquitinase inhibitor of 19S RP, resulting in inhibition of NF-kB pathway and reactivation of proapoptotic protein p53. In addition, in a murine xenograft model of human lung cancer A549, treatment with AC17 suppresses tumor growth in a manner associated with proteasome inhibition, NF-kB blockage, and p53 reactivation. These results suggest that 4-arylidene curcumin analogs are novel 19S deubiquitinase inhibitors with great potential for anticancer drug development.
Gametogenetin-binding protein 2 (GGNBP2) is encoded in human chromosome 17q12-q23, a region known as a breast and ovarian cancer susceptibility locus. GGNBP2, also referred to ZFP403, has a single C2H2 zinc finger and a consensus LxxLL nuclear receptor-binding motif. Here, we demonstrate that GGNBP2 expression is reduced in primary human breast tumors and in breast cancer cell lines, including T47D, MCF-7, LCC9, LY2, and MDA-MB-231 compared with normal, immortalized estrogen receptor α (ERα) negative MCF-10A and MCF10F breast epithelial cells. Overexpression of GGNBP2 inhibits the proliferation of T47D and MCF-7 ERα positive breast cancer cells without affecting MCF-10A and MCF10F. Stable GGNBP2 overexpression in T47D cells inhibits 17β-estradiol (E2)-stimulated proliferation as well as migration, invasion, anchorage-independent growth in vitro, and xenograft tumor growth in mice. We further demonstrate that GGNBP2 protein physically interacts with ERα, inhibits E2-induced activation of estrogen response element-driven reporter activity, and attenuates ER target gene expression in T47D cells. In summary, our in vitro and in vivo findings suggest that GGNBP2 is a novel breast cancer tumor suppressor functioning as a nuclear receptor corepressor to inhibit ERα activity and tumorigenesis.
#5061 BACKGROUND: Accumulating evidence suggests that obesity is a high risk factor for breast cancer among post-menopausal women, which can at least partially be explained by the contribution of adipose tissue to local and circulating estrogen. In response to tumor cell-secreted cytokines, adipose stromal cells (ASCs) express a large amount of aromatase, a key enzyme in estrogen biosynthesis and a clinically proven target for breast cancer therapy. Increased estrogen production from ASCs in turn stimulates hormone-dependent tumor growth, creating a “vicious cycle” between estrogen-dependent tumor cells and estrogen-producing ASCs that is conducive to mammary tumorigenesis. In contrast to our knowledge of aromatase expression in tumor-associated ASCs, relatively little is known about its regulation in ASCs under disease-free conditions. Could aromatase expression in ASCs be induced without the presence of tumor cells? Is there any genetic or epigenetic difference in the inducibility of aromatase expression in cancer-free individuals? If so, might the difference be related to breast cancer risk?
 Material and Methods: ASCs were isolated from cancer-free individuals by using blendzyme. ACSs were plated in confluent and subconfluent states for several days and then were harvested for RNA isolation, enzymatic activity and protein study. Specific genes were expressed in ASCs using lentiviral expression system and were depleted by siRNA method. Co-culture system was established using ASC and ZR-75 cell line. In a xenograft model, ASCs were injected with the ZR-75 cells in mammary fat pad.
 Results: Aromatase expression in ASCs can be stimulated up to several hundred folds by cell shape changes induced by various physical or chemical stimuli. Our work uncovered several key signal-transducing molecules including Inhibitory kB Kinases (IKKs) in mediating the cell shape-triggered aromatase expression. Unexpectedly, activation of aromatase gene expression following cell shape change does not involve activation of NFkB, a downstream effector of IKKs. Rather, aromatase induction following cell shape change positively correlated with the expression level of CEBPβ; and CEBPβ knockdown severely impaired aromatase expression. Significant increase in aromatase expression was due to activation of the same breast cancer-associated promoters that are robustly stimulated in intratumoral adipose tissue. In a coculture and invivo xenograft model, ACSs were able to trigger E2 responsive genes as well as stimulate early tumor occurence in ZR-75 cells, respectively.
 Discussion: Our study suggests that genetic and epigenetic alterations in aromatase-inducing signaling pathway may result in excessive estrogen production and thus breast cancer development. Excess aromatase produced by the stromal cells are capable of initiating tumor in surrounding breast epithelial cells. Study further uncovers a previously unappreciated paradigm for regulation of aromatase expression in adipose tissue, which should have a far-reaching impact on risk assessment and prevention of breast cancer. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 5061.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.